Risk factors for early recurrence after discontinuing lithium in bipolar disorder
Background Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium. Methods We compared factors for association with recurrences of BD within 12 months o...
Saved in:
Published in | Bipolar disorders Vol. 24; no. 7; pp. 720 - 725 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
Wiley Subscription Services, Inc
01.11.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 1398-5647 1399-5618 1399-5618 |
DOI | 10.1111/bdi.13206 |
Cover
Abstract | Background
Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium.
Methods
We compared factors for association with recurrences of BD within 12 months of discontinuing long‐term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium‐discontinuation and prior treatment duration.
Results
Among 227 BD subjects who received lithium for 4.47 [CI: 3.89–5.04] years and then discontinued, rapid treatment‐discontinuation, and stopping for medical reasons were strongly associated with new illness‐episodes within 12 months, as were diagnosis (BD‐I > BD‐II), greater morbidity during lithium‐treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment‐discontinuation. Early recurrence was not associated with treatment‐duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD‐I diagnosis remained significantly, independently associated with early illness after lithium‐discontinuation, with no effect of treatment duration.
Conclusions
Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD‐I than BD‐II, and following greater morbidity during lithium‐treatment, but not related to dose or duration of preceding treatment exposure. |
---|---|
AbstractList | Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium.BACKGROUNDTime to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium.We compared factors for association with recurrences of BD within 12 months of discontinuing long-term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium-discontinuation and prior treatment duration.METHODSWe compared factors for association with recurrences of BD within 12 months of discontinuing long-term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium-discontinuation and prior treatment duration.Among 227 BD subjects who received lithium for 4.47 [CI: 3.89-5.04] years and then discontinued, rapid treatment-discontinuation, and stopping for medical reasons were strongly associated with new illness-episodes within 12 months, as were diagnosis (BD-I > BD-II), greater morbidity during lithium-treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment-discontinuation. Early recurrence was not associated with treatment-duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD-I diagnosis remained significantly, independently associated with early illness after lithium-discontinuation, with no effect of treatment duration.RESULTSAmong 227 BD subjects who received lithium for 4.47 [CI: 3.89-5.04] years and then discontinued, rapid treatment-discontinuation, and stopping for medical reasons were strongly associated with new illness-episodes within 12 months, as were diagnosis (BD-I > BD-II), greater morbidity during lithium-treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment-discontinuation. Early recurrence was not associated with treatment-duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD-I diagnosis remained significantly, independently associated with early illness after lithium-discontinuation, with no effect of treatment duration.Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD-I than BD-II, and following greater morbidity during lithium-treatment, but not related to dose or duration of preceding treatment exposure.CONCLUSIONSEarly recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD-I than BD-II, and following greater morbidity during lithium-treatment, but not related to dose or duration of preceding treatment exposure. Background Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium. Methods We compared factors for association with recurrences of BD within 12 months of discontinuing long‐term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium‐discontinuation and prior treatment duration. Results Among 227 BD subjects who received lithium for 4.47 [CI: 3.89–5.04] years and then discontinued, rapid treatment‐discontinuation, and stopping for medical reasons were strongly associated with new illness‐episodes within 12 months, as were diagnosis (BD‐I > BD‐II), greater morbidity during lithium‐treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment‐discontinuation. Early recurrence was not associated with treatment‐duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD‐I diagnosis remained significantly, independently associated with early illness after lithium‐discontinuation, with no effect of treatment duration. Conclusions Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD‐I than BD‐II, and following greater morbidity during lithium‐treatment, but not related to dose or duration of preceding treatment exposure. BackgroundTime to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium.MethodsWe compared factors for association with recurrences of BD within 12 months of discontinuing long‐term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium‐discontinuation and prior treatment duration.ResultsAmong 227 BD subjects who received lithium for 4.47 [CI: 3.89–5.04] years and then discontinued, rapid treatment‐discontinuation, and stopping for medical reasons were strongly associated with new illness‐episodes within 12 months, as were diagnosis (BD‐I > BD‐II), greater morbidity during lithium‐treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment‐discontinuation. Early recurrence was not associated with treatment‐duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD‐I diagnosis remained significantly, independently associated with early illness after lithium‐discontinuation, with no effect of treatment duration.ConclusionsEarly recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD‐I than BD‐II, and following greater morbidity during lithium‐treatment, but not related to dose or duration of preceding treatment exposure. Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk of early illness after discontinuing lithium. We compared factors for association with recurrences of BD within 12 months of discontinuing long-term lithium treatment, using bivariate and multivariable analyses, as well as survival analysis to evaluate latency to new episodes versus rate of lithium-discontinuation and prior treatment duration. Among 227 BD subjects who received lithium for 4.47 [CI: 3.89-5.04] years and then discontinued, rapid treatment-discontinuation, and stopping for medical reasons were strongly associated with new illness-episodes within 12 months, as were diagnosis (BD-I > BD-II), greater morbidity during lithium-treatment, and less education, but neither longer treatment nor serum lithium concentrations. Discontinuation rate was strongly associated with shorter median latency to a new episode (rapid: 3.50; gradual [≥2 weeks]: 10.6 months), even with very early recurrences excluded to avoid potential contributions of emerging illness to treatment-discontinuation. Early recurrence was not associated with treatment-duration of ≥2 or ≥5 years or less. In multivariable logistic regression, rapid discontinuation, stopping for medical reasons, and BD-I diagnosis remained significantly, independently associated with early illness after lithium-discontinuation, with no effect of treatment duration. Early recurrence risk was again much greater after rapid discontinuation of lithium and discontinuing for medical reasons, somewhat greater with BD-I than BD-II, and following greater morbidity during lithium-treatment, but not related to dose or duration of preceding treatment exposure. |
Author | Tondo, Leonardo Contu, Martina Vázquez, Gustavo H. Baldessarini, Ross J. Pinna, Marco |
Author_xml | – sequence: 1 givenname: Ross J. orcidid: 0000-0001-9718-8211 surname: Baldessarini fullname: Baldessarini, Ross J. email: rbaldessarini@mclen.harvard.edu organization: Harvard Medical School – sequence: 2 givenname: Marco surname: Pinna fullname: Pinna, Marco organization: Cagliari & Rome – sequence: 3 givenname: Martina surname: Contu fullname: Contu, Martina organization: Cagliari & Rome – sequence: 4 givenname: Gustavo H. surname: Vázquez fullname: Vázquez, Gustavo H. organization: Queen's University School of Medicine – sequence: 5 givenname: Leonardo surname: Tondo fullname: Tondo, Leonardo organization: Cagliari & Rome |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35319801$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUlLBDEQhYMo7gf_gAS86GE0Sy_J0V1BEEXPIZNUNNqTjEk3Mv_eODNeROtSdfjeo3hvC62GGAChPUqOaZmTsfXHlDPSrKBNyqUc1Q0Vq_NblLtqN9BWzm-E0IaReh1t8JpTKQjdRA-PPr9jp00fU8YuJgw6dTOcwAwpQTCAteshYeuziaH3YfDhBXe-f_XDBPuAx34aOz0HYrKQdtCa012G3eXeRs9Xl0_nN6O7--vb89O7kWGCNyNteNtUhGgKFCwIKaUmjRVjZmshuWS2tdowDk3Na9caLpxwxgnGmZCkdXwbHS58pyl-DJB7NSkvQtfpAHHIijVVYduKVAU9-IW-xSGF8p1iLRdc1JLxQu0vqWE8AaumyU90mqmfsApwsgBMijkncMr4Xve-xJK07xQl6rsOVepQ8zqK4uiX4sf0L3bp_uk7mP0PqrOL24XiC41tmAY |
CitedBy_id | crossref_primary_10_3390_su15054128 crossref_primary_10_2174_2666082219666221228123312 crossref_primary_10_7759_cureus_43604 crossref_primary_10_1177_02698811231166460 crossref_primary_10_1186_s40345_024_00339_6 |
Cites_doi | 10.1176/ajp.154.4.551 10.1111/bdi.12105 10.1176/appi.ajp.2007.06101639 10.1176/appi.ajp.2010.09060880 10.1159/000506868 10.1176/appi.ajp.2018.17091001 10.1001/archpsyc.1997.01830130055011 10.1017/S0033291720004778 10.1001/archpsyc.1993.01820180046005 10.1177/2045125314540297 10.1159/000497334 10.1111/bdi.13017 10.1111/j.1399-5618.2007.00389.x |
ContentType | Journal Article |
Copyright | 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Copyright © 2022 John Wiley & Sons A/S |
Copyright_xml | – notice: 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: Copyright © 2022 John Wiley & Sons A/S |
DBID | AAYXX CITATION NPM 7TK 7X8 |
DOI | 10.1111/bdi.13206 |
DatabaseName | CrossRef PubMed Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Neurosciences Abstracts PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1399-5618 |
EndPage | 725 |
ExternalDocumentID | 35319801 10_1111_bdi_13206 BDI13206 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: Bruce J Anderson Foundation funderid: 2021‐22 – fundername: Aretaeus Foundation of Rome – fundername: McLean Private Donors Psychiatric Research Fund – fundername: Bruce J Anderson Foundation grantid: 2021-22 |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 23N 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION NPM 7TK AAMMB AEFGJ AGXDD AIDQK AIDYY 7X8 |
ID | FETCH-LOGICAL-c2836-ac376400a1e1ede8999a06d8b2d589392d7dac23e6535f7c38f8fcf82328907f3 |
IEDL.DBID | DR2 |
ISSN | 1398-5647 1399-5618 |
IngestDate | Fri Jul 11 15:07:38 EDT 2025 Fri Jul 25 21:06:28 EDT 2025 Wed Feb 19 02:25:56 EST 2025 Thu Apr 24 23:01:24 EDT 2025 Tue Jul 01 04:32:31 EDT 2025 Wed Jan 22 16:26:49 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | recurrence lithium treatment bipolar disorder risk factors discontinuation |
Language | English |
License | 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2836-ac376400a1e1ede8999a06d8b2d589392d7dac23e6535f7c38f8fcf82328907f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-9718-8211 |
PMID | 35319801 |
PQID | 2738385923 |
PQPubID | 2045186 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_2642327404 proquest_journals_2738385923 pubmed_primary_35319801 crossref_citationtrail_10_1111_bdi_13206 crossref_primary_10_1111_bdi_13206 wiley_primary_10_1111_bdi_13206_BDI13206 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2022 |
PublicationDateYYYYMMDD | 2022-11-01 |
PublicationDate_xml | – month: 11 year: 2022 text: November 2022 |
PublicationDecade | 2020 |
PublicationPlace | Denmark |
PublicationPlace_xml | – name: Denmark – name: Hoboken |
PublicationTitle | Bipolar disorders |
PublicationTitleAlternate | Bipolar Disord |
PublicationYear | 2022 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2018; 175 2013; 15 2014; 4 2021; 23 1993; 50 1997; 54 2019; 88 2021 1997; 154 2010; 167 2007; 164 2007; 9 2020; 89 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_14_1 |
References_xml | – volume: 54 start-page: 49 year: 1997 end-page: 55 article-title: Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment publication-title: Arch Gen Psychiatry – volume: 9 start-page: 435 year: 2007 end-page: 442 article-title: Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study publication-title: Bipolar Disord – volume: 164 start-page: 1817 year: 2007 end-page: 1824 article-title: Recurrences of bipolar disorder in pregnancy: prospective study of mood‐stabilizer discontinuation publication-title: Am J Psychiatry – volume: 50 start-page: 448 year: 1993 end-page: 455 article-title: Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar mood disorders publication-title: Arch Gen Psychiatry – volume: 88 start-page: 65 year: 2019 end-page: 70 article-title: Effects of treatment discontinuation in clinical psychopharmacology publication-title: Psychother Psychosom – volume: 89 start-page: 283 year: 2020 end-page: 306 article-title: Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications publication-title: Psychother Psychosom – volume: 4 start-page: 198 year: 2014 end-page: 219 article-title: Role of long‐acting injectable antipsychotics in schizophrenia: a critical appraisal publication-title: Ther Adv Psychopharmacol – volume: 175 start-page: 765 year: 2018 end-page: 773 article-title: 20‐year nation‐wide follow‐up study on discontinuation of antipsychotic treatment in first‐episode schizophrenia publication-title: Am J Psychiatry – year: 2021 article-title: Twenty‐year effects of antipsychotics in schizophrenia and affective psychotic disorders publication-title: Psychol Med – volume: 23 start-page: 14 year: 2021 end-page: 23 article-title: Prevention of suicidal behavior in bipolar disorder publication-title: Bipolar Disord – volume: 154 start-page: 551 year: 1997 end-page: 553 article-title: Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study publication-title: Am J Psychiatry – volume: 167 start-page: 934 year: 2010 end-page: 941 article-title: Discontinuation rate vs. recurrence risk following long‐term antidepressant treatment in major depressive disorder patients publication-title: Am J Psychiatry – volume: 15 start-page: 645 year: 2013 end-page: 649 article-title: Effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation‐induced refractoriness publication-title: Bipolar Disord – ident: e_1_2_9_8_1 doi: 10.1176/ajp.154.4.551 – ident: e_1_2_9_13_1 doi: 10.1111/bdi.12105 – ident: e_1_2_9_6_1 doi: 10.1176/appi.ajp.2007.06101639 – ident: e_1_2_9_10_1 doi: 10.1176/appi.ajp.2010.09060880 – ident: e_1_2_9_2_1 doi: 10.1159/000506868 – ident: e_1_2_9_11_1 doi: 10.1176/appi.ajp.2018.17091001 – ident: e_1_2_9_9_1 doi: 10.1001/archpsyc.1997.01830130055011 – ident: e_1_2_9_12_1 doi: 10.1017/S0033291720004778 – ident: e_1_2_9_7_1 doi: 10.1001/archpsyc.1993.01820180046005 – ident: e_1_2_9_14_1 doi: 10.1177/2045125314540297 – ident: e_1_2_9_4_1 doi: 10.1159/000497334 – ident: e_1_2_9_5_1 doi: 10.1111/bdi.13017 – ident: e_1_2_9_3_1 doi: 10.1111/j.1399-5618.2007.00389.x |
SSID | ssj0016205 |
Score | 2.401979 |
Snippet | Background
Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with... Time to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with the risk... BackgroundTime to a new episode of bipolar disorder (BD) is shorter after discontinuing lithium rapidly. We now address this and other factors associated with... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 720 |
SubjectTerms | Bipolar disorder Diagnosis discontinuation Latency Lithium lithium treatment Morbidity recurrence Risk factors Survival analysis |
Title | Risk factors for early recurrence after discontinuing lithium in bipolar disorder |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbdi.13206 https://www.ncbi.nlm.nih.gov/pubmed/35319801 https://www.proquest.com/docview/2738385923 https://www.proquest.com/docview/2642327404 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB5VPay4LMtjoWwXGcRhL6maOHFccdqlVAUJJCoq9YAU-RVt1CWt2ubCr2fGeYjCIiFukTKRHdsz843t-QbgzThXCGodD4RRNkAPFQaKCx0YqXlkJTp05W9bfBbzZfxxlax68LbNhan5IboNN9IMb69JwZXe_6Lk2hYjyv8luu2QC-LNny466qhQRP76IgIcGSQiThtWIbrF03157Iv-AJjHeNU7nNlD-NZ2tb5nsh5VBz0yP35jcfzPfzmD0waIsut65TyCnisfw8mn5qj9CXxZFPs1a8rxMIS2zBEXMtvRBr1PEWS-vjijvN4N1Zuo0AsyRPW3RfWdFSXTxZbiZhLwBJ9PYTl7__XdPGjqLwQGQYcIlEHrgzquQhc66zAyw4kTVurIJghzJpFNrTIRdyLhSZ4aLnOZm1wiSJMYc-f8HPrlpnTPgcnUmFTqSTiRYaxjPdFoKbUZhzY2-diZAVy1M5GZhpycamTcZW2QgkOU-SEawOtOdFszctwnNGynM2uUcp9RFhKXCULaAbzqXqM60RmJKt2mQhlBJ9dpPI4H8KxeBl0rnOwVenTsrJ_Mvzef3Uw_-IcX_y56AQ8iSq3weY5D6B92lbtEwHPQL_3K_glgW_o- |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-QwDLZ4SAsXYBcWhtdmVxy4dDRt2jQjceGp4SktAokLqppHtRXQQTC98Oux04dgAQlxq1RXSePY_hzHNsBGL0sR1FruCZ0aDy2U76VcKE9LxQMj0aCn7rbFmRhchkdX0dUYbDW5MFV9iPbAjSTD6WsScDqQfiHlyuRdSgAW4zDp4nMEic7b4lG-CNwFRoQ40otEGNd1hegeT_vpa2v0BmK-RqzO5BzMwnUz2eqmyU23HKmufvqvjuNX_2YOZmosyrarzfMdxmzxA76d1tH2efh7nj_esLojD0N0yyyVQ2YPdEbvsgSZazHOKLV3SC0nSjSEDIH9v7y8Y3nBVH5PrjMRuBqfC3B5sH-xO_DqFgyeRtwhvFSjAkIxT33rW2PROUPeCSNVYCJEOv3AxCbVAbci4lEWay4zmelMIk6T6HZn_CdMFMPCLgGTsdaxVH2_L_1QhaqvUFkq3fNNqLOe1R3YbFiR6Lo-ObXJuE0aPwWXKHFL1IE_Lel9VZTjPaLVhp9JLZePCSUicRkhqu3A7_Y1ShSFSdLCDkukERS8jsNe2IHFah-0o3BSWWjUcbKOmx8Pn-zsHbqH5c-T_oKpwcXpSXJyeHa8AtMBZVq4tMdVmBg9lHYN8c9Irbtt_gwKT_5c |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkFAvUKCFpVswiAOXrDZx4njVU1tYsUARIJA4VIriR0QEZFewufTXM-M8VB6VELdImciOxzPzjT0PgJ1-liKotdwTOjUeWijfS7lQnpaKB0aiQU9dtMWJOLgMD6-iqxn43uTCVPUh2gM3kgynr0nAJyb7R8iVyXuU_ys-wFwo0EwSIjpva0f5InDxi4hwpBeJMK7LClEYT_vpU2P0AmE-BazO4gwX4U8z1yrQ5KZXTlVP_31WxvGdP_MJFmokyn5UW2cJZmyxDPO_67v2FTg7zx9uWN2PhyG2ZZaKIbN7OqF3OYLMNRhnlNg7poYTJZpBhrD-Oi_vWF4wlU_IcSYCV-HzM1wO9y9-HXh1AwZPI-oQXqpR_aCQp771rbHomiHnhJEqMBHinEFgYpPqgFsR8SiLNZeZzHQmEaVJdLoz_gVmi3Fh14DJWOtYqoE_kH6oQjVQqCqV7vsm1Fnf6g7sNpxIdF2dnJpk3CaNl4JLlLgl6sB2SzqpSnK8RtRt2JnUUvmQUBoSlxFi2g5sta9RnuiSJC3suEQaQVfXcdgPO7BabYN2FE4KC006TtYx8__DJz_3Ru5h_e2kmzB_ujdMjkcnR1_hY0BpFi7nsQuz0_vSfkPwM1UbbpM_AhIh_Qs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+for+early+recurrence+after+discontinuing+lithium+in+bipolar+disorder&rft.jtitle=Bipolar+disorders&rft.au=Baldessarini%2C+Ross+J&rft.au=Pinna%2C+Marco&rft.au=Contu%2C+Martina&rft.au=V%C3%A1zquez%2C+Gustavo+H&rft.date=2022-11-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1398-5647&rft.eissn=1399-5618&rft.volume=24&rft.issue=7&rft.spage=720&rft.epage=725&rft_id=info:doi/10.1111%2Fbdi.13206&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1398-5647&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1398-5647&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1398-5647&client=summon |